Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Cytomegalovirus
100%
Letermovir
100%
Cytomegalovirus Reactivation
50%
Clinically Significant
35%
Confidence Interval
28%
Hazard Ratio
28%
CMV Infection
28%
Post-transplantation Cyclophosphamide (PTCy)
28%
High Risk
21%
Transplantation
14%
Overall Survival
14%
Mortality Hazard
14%
Mismatched Related Donor
14%
Serum IgG Level
14%
Risk Factors
7%
Retrospective Cohort Study
7%
Prednisone
7%
Graft-versus-host Disease (GvHD)
7%
Multivariate Analysis
7%
Overall Mortality
7%
Increased Incidence
7%
Infection Rate
7%
Cancer Center
7%
Single Center
7%
Low Incidence
7%
Jewish
7%
Cytomegalovirus Infection
7%
Cytomegalovirus Prophylaxis
7%
Cytomegalovirus Viremia
7%
Steroid Use
7%
Extended Duration
7%
Mortality Benefit
7%
Non-relapse Mortality
7%
Graft-versus-host Disease Prophylaxis
7%
Haploidentical Transplantation
7%
Umbilical Cord Blood Transplantation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cytomegalovirus
100%
Letermovir
100%
Cytomegalovirus Infection
25%
Cyclophosphamide
20%
Overall Survival
10%
Cohort Study
5%
Prednisone
5%
Malignant Neoplasm
5%
Immunosuppressive Agent
5%
Acute Graft Versus Host Disease
5%
Viremia
5%
Antibiotic as 48
5%
Immunology and Microbiology
Stem Cell Transplant
100%
Cytomegalovirus
100%
Cyclophosphamide
20%
Allogeneic Stem Cell Transplantation
20%
Overall Survival
10%
Viremia
5%
Acute Graft Versus Host Disease
5%
Prednisone
5%
Cytomegalovirus Infection
5%
Umbilical Cord Blood
5%